Literature DB >> 27542974

True Resistant Hypertension Following Observed Drug Ingestion: A Systematic Evaluation.

Jill Bunker1, Choon-Lan Chang2, Neil Chapman1, Neil Poulter3, Simon Thom2, Lucy Thornton-Jones1, Peter Sever2.   

Abstract

The authors investigated the role of poor drug adherence in treatment-resistant hypertension following observed drug ingestion in 102 patients. Median blood pressures (BPs) were 170/91 mm Hg at referral, 153/84 mm Hg prior to, and 142/79 mm Hg during a 4- to 6-hour period after drug ingestion. Median daytime ambulatory BP monitoring (ABPM) over the following 24 hours was 142/80 mm Hg. Median BP at a final follow-up clinic visit was 147/79 mm Hg. The cumulative number of patients achieving a goal of <140/90 mm Hg in clinic or <135/85 mm Hg mean on ABPM was 57 (56%), with a further nine (9%) controlled at the final follow-up clinic visit. Thus, 65% of patients achieved a systolic BP <140 mm Hg at any point immediately prior to, or after, drug ingestion; the residual 35% were considered to have true resistant hypertension. In conclusion, among patients with suspected resistant hypertension, a minority were truly treatment-resistant following observed drug ingestion and BP monitoring. ©2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27542974      PMCID: PMC8030817          DOI: 10.1111/jch.12896

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  16 in total

Review 1.  Resistant hypertension.

Authors:  Robert H Fagard
Journal:  Heart       Date:  2012-02       Impact factor: 5.994

2.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

3.  Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.

Authors:  Murray D Esler; Henry Krum; Markus Schlaich; Roland E Schmieder; Michael Böhm; Paul A Sobotka
Journal:  Circulation       Date:  2012-12-18       Impact factor: 29.690

4.  Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure.

Authors:  Fadl Elmula Mohamed Fadl Elmula; Pavel Hoffmann; Eigil Fossum; Magne Brekke; Eyvind Gjønnæss; Ulla Hjørnholm; Vibeke N Kjær; Morten Rostrup; Sverre E Kjeldsen; Ingrid Os; Aud-E Stenehjem; Aud Høieggen
Journal:  Hypertension       Date:  2013-07-08       Impact factor: 10.190

5.  Effect of spironolactone on blood pressure in subjects with resistant hypertension.

Authors:  Neil Chapman; Joanna Dobson; Sarah Wilson; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Journal:  Hypertension       Date:  2007-02-19       Impact factor: 10.190

6.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

7.  Hypertension management in England: a serial cross-sectional study from 1994 to 2011.

Authors:  Emanuela Falaschetti; Jennifer Mindell; Craig Knott; Neil Poulter
Journal:  Lancet       Date:  2014-05-31       Impact factor: 79.321

8.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

9.  International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension.

Authors:  Markus P Schlaich; Roland E Schmieder; George Bakris; Peter J Blankestijn; Michael Böhm; Vito M Campese; Darrel P Francis; Guido Grassi; Dagmara Hering; Richard Katholi; Sverre Kjeldsen; Henry Krum; Felix Mahfoud; Giuseppe Mancia; Franz H Messerli; Krzysztof Narkiewicz; Gianfranco Parati; Krishna J Rocha-Singh; Luis M Ruilope; Lars C Rump; Domenic A Sica; Paul A Sobotka; Costas Tsioufis; Oliver Vonend; Michael A Weber; Bryan Williams; Thomas Zeller; Murray D Esler
Journal:  J Am Coll Cardiol       Date:  2013-09-18       Impact factor: 24.094

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

View more
  6 in total

Review 1.  Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not?

Authors:  Patricia Van der Niepen; Patrick Rossignol; Jean-Philippe Lengelé; Elena Berra; Pantelis Sarafidis; Alexandre Persu
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

Review 2.  Multidisciplinary Approach in the Treatment of Resistant Hypertension.

Authors:  S A Potthoff; O Vonend
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

3.  Optimizing identification of resistant hypertension: Computable phenotype development and validation.

Authors:  Caitrin W McDonough; Kyle Babcock; Kristen Chucri; Dana C Crawford; Jiang Bian; François Modave; Rhonda M Cooper-DeHoff; William R Hogan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-08-26       Impact factor: 2.890

4.  Will the recent hypertension trials change the guidelines?

Authors:  Peter Sever
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2017 Apr-Jun       Impact factor: 1.636

5.  Renal denervation: An uncertain future.

Authors:  Peter Sever
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Apr-Jun       Impact factor: 1.636

6.  True Resistant Hypertension Following Observed Drug Ingestion: A Systematic Evaluation.

Authors:  Jill Bunker; Choon-Lan Chang; Neil Chapman; Neil Poulter; Simon Thom; Lucy Thornton-Jones; Peter Sever
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-20       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.